In Mexico, anemia in chronic kidney disease is managed by hematologists. Anemia is a deficit of healthy red blood cells or hemoglobin that limits how much oxygen the blood can carry to tissues. It affects roughly 1.9 billion people worldwide — about a quarter of the global population — with the highest burden in women of reproductive age, young children, and people with chronic disease (WHO 2021).
Anemia (ICD-10: D50-D64) is a reduction in red blood cell mass or hemoglobin concentration below the threshold needed to deliver adequate oxygen to peripheral tissues. The World Health Organization defines anemia in adults as hemoglobin below 13.0 g/dL in men, below 12.0 g/dL in non-pregnant women, and below 11.0 g/dL in pregnant women, with lower cut-offs for children that vary by age. Mechanistically, anemia arises from one of three pathways: decreased red cell production (iron, B12, folate, or erythropoietin deficiency; bone marrow failure; chronic inflammation), increased destruction (hemolysis from autoimmune, hereditary, or mechanical causes), or acute or chronic blood loss (gastrointestinal, menstrual, surgical). The condition is classified morphologically by mean corpuscular volume (MCV) into microcytic (MCV under 80 fL — typically iron deficiency, thalassemia, or anemia of chronic disease), normocytic (MCV 80-100 fL — acute blood loss, chronic disease, renal failure, early hemolysis), and macrocytic (MCV over 100 fL — B12 or folate deficiency, alcohol, liver disease, myelodysplastic syndrome).
The key symptoms of Anemia in chronic kidney disease are: Persistent fatigue and reduced exercise tolerance that develops gradually over weeks to months — the most common presenting symptom, often the only one in mild anemia., Shortness of breath on exertion, then at rest as the deficit worsens, because cardiac output must rise to compensate for reduced oxygen delivery., Pale skin, conjunctivae, nail beds, and palmar creases — usually visible once hemoglobin falls below 9-10 g/dL, more reliable in the conjunctiva than the face., Lightheadedness or dizziness on standing, sometimes with brief syncope, from reduced oxygen reserve and orthostatic intolerance., Resting tachycardia (heart rate above 100) and palpitations as the heart compensates by beating faster., Headache, poor concentration, irritability, and brain fog — particularly common in iron deficiency even before anemia develops., Cold hands and feet from peripheral vasoconstriction and reduced tissue oxygenation..
Workup begins with a complete blood count and reticulocyte count. The complete blood count yields hemoglobin (defines anemia), MCV (classifies morphology), red cell distribution width (RDW; high in iron deficiency, narrow in thalassemia trait), and white cell and platelet counts (other lineages flag marrow failure or hemolysis). The reticulocyte count separates production problems (low or inappropriately normal reticulocytes) from destruction or blood loss (high reticulocytes). MCV directs the next step: in microcytic anemia, order ferritin, transferrin saturation, and iron studies — ferritin under 30 ng/mL confirms iron deficiency in most settings, while ferritin 30-100 with transferrin saturation under 20% suggests iron deficiency overlapping with inflammation, and high ferritin with low saturation is typical of anemia of chronic disease. Hemoglobin electrophoresis is added when MCV is disproportionately low for the degree of anemia or when ancestry suggests thalassemia. In macrocytic anemia, serum B12 and folate are first-line; methylmalonic acid and homocysteine resolve borderline B12 values. In normocytic anemia, evaluate renal function, thyroid function, inflammatory markers, and consider a peripheral smear and reticulocyte index. Hemolysis is supported by elevated LDH, indirect bilirubin, and reticulocytes with low haptoglobin, then characterized by direct Coombs test and smear morphology. Bone marrow biopsy is reserved for unexplained pancytopenia, suspected myelodysplastic syndrome, or refractory anemia. In adult men and post-menopausal women with newly identified iron-deficiency anemia, upper and lower gastrointestinal endoscopy is recommended to exclude a bleeding source per BSH 2021 and ACG guidance.
Outlook depends entirely on the underlying cause. Iron, B12, and folate deficiency anemias correct fully within 2-3 months of adequate replacement, and recurrence is prevented by treating the source. Anemia of chronic kidney disease is well controlled in 80-90% of patients with iron and erythropoiesis-stimulating agents, although it requires lifelong management. Hereditary anemias such as thalassemia major and sickle cell disease have improving but still limited life expectancy without curative transplant or gene therapy; mild trait carriers have a normal lifespan. Aplastic anemia 5-year survival now exceeds 80% with matched sibling transplant or modern immunosuppression. Across the board, untreated severe anemia carries a 30-50% increased risk of cardiovascular events, falls, hospitalization, and mortality in older adults, and contributes to roughly 20% of maternal deaths globally. The decisive prognostic factors are speed of diagnosis, identification of the underlying cause, and adherence to repletion and surveillance.
A hematologist should be involved when anemia is severe (Hb under 8 g/dL without obvious cause), unresponsive to first-line therapy, pancytopenic, hemolytic, transfusion-dependent, suspected to be inherited, or accompanied by abnormal smear findings such as blasts or schistocytes. Most uncomplicated iron, B12, or folate deficiency is well managed in primary care once the underlying source is identified.
Find specialists →Reticulocyte response to iron, B12, or folate appears within 5-10 days and peaks at 7-14 days. Hemoglobin rises by roughly 1 g/dL every 2-3 weeks on oral iron and 1-2 weeks on IV iron or parenteral B12. Full hemoglobin normalization typically takes 6-12 weeks. Iron stores (ferritin) take longer — continue oral iron for at least 3 months after hemoglobin normalizes, or until ferritin exceeds 100 ng/mL, to prevent rapid relapse. Severe symptomatic anemia treated with transfusion improves within hours; durable correction still depends on treating the underlying cause.
Moderate aerobic exercise is safe and beneficial once hemoglobin is above 10 g/dL. Severe anemia (Hb under 8 g/dL) warrants rest and prompt treatment before resuming exertion because cardiac output reserve is reduced. After iron repletion, exercise tolerance typically returns to baseline within 4-8 weeks. Athletes with persistent fatigue and normal hemoglobin should still have ferritin checked — performance can be impaired by iron deficiency before frank anemia develops.
Look for board certification in hematology, experience with IV iron protocols, comfort interpreting peripheral smears and hemoglobin electrophoresis, and access to a transfusion service. For inherited hemoglobinopathies, choose a center with a dedicated sickle cell or thalassemia program. Continuity of care matters — anemia workups often unfold over multiple visits and labs.
Medically reviewed by AIHealz Medical Editorial Board · May 12, 2026
Ranked by patient outcomes and specialized experience.
Verifying top specialists in Mexico.
Apply as specialist →Specialists who treat Anemia in chronic kidney disease. Get expert guidance and personalized care.